Reaney et al. have recently reviewed PROMs used in published phase 3 type 2 diabetes mellitus trials of GLP-1 receptor agonists, novel insulins, SGLT-2 inhibitors and DPP-4 inhibitors [16]. The gene discussed is GLP1R; the disease is diabetes mellitus.